Future Directions for ctDNA-Based Testing in MIBC
The experts conclude this program by discussing future biomarker-guided approaches in bladder cancer treatment.
EP: 1.Challenges in MIBC Management and Opportunities for ctDNA-based Testing
EP: 2.Exploratory Analysis of ctDNA in MIBC from CheckMate 274
EP: 3.Evaluating ctDNA Biomarkers in MIBC from SunRISe-4
EP: 4.Opportunities for Guiding Neoadjuvant Treatment Decisions with ctDNA in MIBC
EP: 5.Assessing ctDNA-Guided Therapy in MIBC in IMvigor011
EP: 6.Implications for ctDNA-Guided Adjuvant Decision-Making in MIBC
EP: 7.Future Directions for ctDNA-Based Testing in MIBC
The experts conclude this program by discussing future biomarker-guided approaches in bladder cancer treatment. They propose designing studies that use molecular markers to guide treatment intensification or de-escalation. The conversation explores potential research directions, emphasizing the need for personalized, adaptive treatment strategies. Dr. Meeks and Dr. Tan express optimism about the future of molecular medicine, highlighting how advanced testing might improve patient outcomes. Their dialogue underscores the transformative potential of precision medicine in understanding and treating muscle-invasive bladder cancer. They critically examine current limitations in treatment selection, discussing how molecular markers could provide more refined, patient-specific approaches. The conversation reveals the growing potential of biomarker-guided strategies to revolutionize clinical decision-making and improve patient care.
